Novo Nordisk is acquiring Omeros’ MASP-3 inhibitor, zaltenibart, to advance its development for rare blood and kidney disorders. After Omeros paused its phase 3 preparations in paroxysmal nocturnal hemoglobinuria (PNH), Novo Nordisk will launch a global trial. The deal could bring Omeros up to $2.1B, including $340M upfront and milestone payments, plus royalties.
Novo Nordisk Pens $2.1B Deal for Omeros’ Stalled PNH Drug
Share: